Is GlaxoSmithKline plc A Better Dividend Stock Than Legal & General Group Plc And Berkeley Group Holdings PLC?

Should you ditch Legal & General Group Plc (LON: LGEN) and Berkeley Group Holdings PLC in favour of GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With GlaxoSmithKline (LSE: GSK) having announced that dividends are set to flatline over the next couple of years, a number of investors may be concerned about its income prospects. After all, a key component of income investing is buying shares in companies that can raise dividends at a faster pace than inflation.

However, just because GlaxoSmithKline’s dividend is due to remain at the current level over the medium term, it’s not a company to avoid. Quite the contrary. GlaxoSmithKline offers a high yield of 5.3% and has excellent long-term dividend growth prospects.

A key reason for this is the company’s drugs pipeline. It’s relatively well diversified and has the potential to deliver key, blockbuster drugs in the coming years. In particular, GlaxoSmithKline’s ViiV Healthcare unit has bright prospects and with major cost savings set to be delivered moving forward, GlaxoSmithKline’s bottom line is set to rapidly expand. In fact, its earnings are due to rise by 13% this year and by a further 6% next year.

Furthermore, GlaxoSmithKline remains an appealing defensive play. Its business model is less positively correlated to the wider economy than is the case for a number of its index peers. This means that while stocks in other sectors may be forced to slash dividends if the global economy undergoes a challenging period, GlaxoSmithKline may be able to raise them.

Less certainty

That concern surrounding cyclicality and the potential for lower profits has held back shares in prime property developer Berkeley (LSE: BKG). They’ve fallen by 23% since the turn of the year as investors have become wary about London property valuations in particular – especially with the taxation changes that are being put in place. As such, the outlook for Berkeley is perhaps less certain than it was a year ago, although the company is still forecast to deliver profit growth in each of the next two financial years.

With Berkeley set to pay out 866p per share (30.3% of its current share price) by September 2021 in dividends, its income appeal remains very high. And with earnings per share set to be around 400p in the next financial year alone, it seems to have a relatively large amount of headroom when making its shareholder payouts.

Future looks bright

On the topic of headroom, Legal & General (LSE: LGEN) has scope to briskly increase dividends due to it having a dividend coverage ratio of 1.4. And with Legal & General’s bottom line forecast to rise by 8% this year and by a further 7% next year, its dividend outlook is very bright. Furthermore, with the company trading on a price-to-earnings (P/E) ratio of just 11.9, there’s plenty of scope for a major upward rerating over the medium-to-long term.

Legal & General’s yield currently stands at 6%, which makes it among the highest yielding stocks in the FTSE 100. This may lead many investors to determine that it’s a better income play than GlaxoSmithKline – especially since it’s expected to raise dividends by 7.7% next year, while GlaxoSmithKline’s payout is due to flatline. However, with both Legal & General and Berkeley having more cyclical business models than GlaxoSmithKline and offering less defensive qualities, the healthcare play seems to be the best dividend buy of what’s a very appealing group of income stocks.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Berkeley Group Holdings, GlaxoSmithKline, and Legal & General Group. The Motley Fool UK has recommended Berkeley Group Holdings and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »